USPatentGranted
B2

Chemokine receptor antagonists and use thereof

Granted 23 Oct 2012 · 2 office actions

Life of the patent

3 dated events
⤢ drag to zoom2007200820092010201120122013Prosecution
Prosecutionhover for detail · click to open

Abstract

The present invention relates to a compound represented by formula (I): [structure] wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy.

Claims

15 · 2 independent · depth 4
123456789101112131415
15 granted claims

Classifications

4 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61P35/00
Section C — Chemistry; metallurgy
  • C07D471/10
USPC · US Patent Classification
544/127546/16

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency
6.0 y
2,188 days filing → grant
Office actions
1
after a restriction
Responses
2
no RCE
Examiner
Janet Andres
art unit 1625 · TC 1600
Citations: 15 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Log in to unlock

Priority chain

1 priority documents
›Priority documents — 1
TypeDocumentDate
related publicationUS 20090118279 A17 May 2009

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Log in to unlock

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.

Log in to unlock